Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenue	$ 132,257	$ 105,946	$ 83,417
Gross Profit	32,750	25,282	18,746
Gross profit	99,507	80,664	64,671
Operating expenses:
Research and development	16,199	16,571	16,738
Clinical and regulatory affairs	8,679	6,343	4,439
Marketing and sales	63,588	53,953	44,655
General and administrative	21,409	20,266	15,525
Contract termination and business acquisition expenses	0	422	1,730
Settlement costs	0	(5,000)	0
Total operating expenses	109,875	102,555	83,087
Loss from operations	(10,368)	(21,891)	(18,416)
Other income (expense):
Interest income	50	30	23
Interest expense	(321)	(7)	(32)
Gain on sale of equipment	0	0	141
Other income (expense), net	3,061	325	(32)
Change in fair value of contingent consideration related to acquisition	(8,500)	(13,700)	(10,500)
Total other expense	(5,710)	(13,352)	(10,400)
Net income (loss) before income tax	(16,078)	(35,243)	(28,816)
Income tax benefit (expense)	10	(531)	86
Net loss before income tax	(16,068)	(35,774)	(28,730)
Foreign currency translation adjustment	(845)	(222)	(30)
Comprehensive income (loss)	$ (16,913)	$ (35,996)	$ (28,760)
Basic loss per share	$ (0.26)	$ (0.60)	$ (0.51)
Weighted average shares - diluted	62,607	59,811	56,592